The market has climbed 3.5% in the last 7 days and is up 20% over the last 12 months, with earnings forecast to grow by 17% annually. In this context of growth, penny stocks—often representing smaller or newer companies—can offer intriguing opportunities when supported by strong financials. This article will explore three such stocks that stand out for their potential to deliver value and growth, making them appealing options for investors seeking under-the-radar opportunities.

Let's explore several standout options from the results in the screener.

CuriosityStream (CURI)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: CuriosityStream Inc. is a media and entertainment company that offers factual content across various channels, with a market cap of $158.89 million.

Operations: The company generated $71.73 million in revenue from its media and entertainment operations focused on factual content delivery.

Market Cap: $158.89M

CuriosityStream Inc., with a market cap of US$158.89 million, is navigating the challenges typical of penny stocks. Despite being unprofitable, it has managed to reduce losses by 32.4% annually over five years and maintains a sufficient cash runway for more than three years due to positive free cash flow growth. The company trades at 52.8% below its estimated fair value, suggesting potential upside according to analysts who predict a 99% price increase. However, concerns include negative return on equity and short-term liabilities exceeding assets by US$1.3 million, alongside an unsustainable dividend yield of 12.69%.

Cheetah Mobile (CMCM)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Cheetah Mobile Inc., along with its subsidiaries, offers internet and artificial intelligence services in China, Hong Kong, Japan, and internationally with a market cap of $92.50 million.

Operations: The company generates revenue from Internet Services amounting to CN¥591.15 million.

Market Cap: $92.5M

Cheetah Mobile Inc., with a market cap of US$92.50 million, faces challenges typical of penny stocks, including ongoing unprofitability and declining earnings over the past five years at 21.6% annually. Despite these hurdles, the company operates debt-free and maintains short-term assets of CN¥3 billion exceeding its liabilities by a significant margin. Recent earnings show minimal revenue change year-over-year at CN¥258.99 million, though net losses have narrowed to CN¥17.48 million from CN¥33.36 million previously. The management team is experienced with an average tenure of 8.4 years, which may provide stability amid volatility in operations and stock performance.

BioStem Technologies (BSEM)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: BioStem Technologies, Inc. focuses on developing, manufacturing, and commercializing placental-derived allografts for advanced wound care and regenerative therapies in the United States with a market cap of $59.10 million.

Operations: The company's revenue is primarily generated from its Vitamins & Nutrition Products segment, which accounts for $37.65 million.

Market Cap: $59.1M

BioStem Technologies, Inc., with a market cap of US$59.10 million, navigates the challenges of penny stocks by focusing on regenerative therapies. Recent board changes bring seasoned leadership, potentially guiding strategic growth. The company is unprofitable but has reduced losses over five years and maintains a positive cash runway exceeding three years due to growing free cash flow. Despite high volatility and negative return on equity, BioStem's short-term assets cover liabilities effectively. The issuance of new patents strengthens its intellectual property portfolio, supporting future product development in advanced wound care solutions amidst ongoing financial restructuring efforts through shelf registration filings and private placements.

Make It Happen

• Click here to access our complete index of 325 US Penny Stocks.
• Seeking Other Investments? We've found 8 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.